Loading...
XNASBDTX
Market cap123mUSD
Dec 23, Last price  
2.19USD
1D
-1.35%
1Q
-52.18%
IPO
-94.16%
Name

Black Diamond Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:BDTX chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
25.80%
Rev. gr., 5y
%
Revenues
0k
Net income
-82m
L-2.46%
-4,602,000-8,931,000-41,143,000-65,479,000-123,203,000-84,520,000-82,442,000
CFO
-67m
L-21.59%
-2,351,000-8,454,000-24,674,000-52,146,000-100,148,000-85,082,000-66,717,000
Earnings
Mar 10, 2025

Profile

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
IPO date
Jan 30, 2020
Employees
65
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
86,897
96,066
129,089
Unusual Expense (Income)
NOPBT
(86,897)
(96,066)
(129,089)
NOPBT Margin
Operating Taxes
(4,399)
(2,393)
Tax Rate
NOPAT
(86,897)
(91,667)
(126,696)
Net income
(82,442)
-2.46%
(84,520)
-31.40%
(123,203)
88.16%
Dividends
Dividend yield
Proceeds from repurchase of equity
71,850
177
729
BB yield
-58.17%
-0.27%
-0.38%
Debt
Debt current
3,113
2,841
320
Long-term debt
44,370
53,439
56,600
Deferred revenue
Other long-term liabilities
Net debt
(83,917)
(67,695)
(154,089)
Cash flow
Cash from operating activities
(66,717)
(85,082)
(100,148)
CAPEX
(33)
(192)
(2,710)
Cash from investing activities
16,346
53,366
130,613
Cash from financing activities
71,932
177
729
FCF
(83,226)
(88,308)
(148,649)
Balance
Cash
131,400
122,807
209,786
Long term investments
1,168
1,223
Excess cash
131,400
123,975
211,009
Stockholders' equity
(417,451)
(336,808)
(244,229)
Invested Capital
559,485
29,959
468,589
ROIC
ROCE
EV
Common stock shares outstanding
43,955
36,326
36,189
Price
2.81
56.11%
1.80
-66.23%
5.33
-83.37%
Market cap
123,513
88.90%
65,386
-66.10%
192,887
-81.71%
EV
39,596
(2,309)
38,798
EBITDA
(86,460)
(95,558)
(128,884)
EV/EBITDA
0.02
Interest
3,909
Interest/NOPBT